AB 2250 is a definitions-focused amendment to the California Cannabis Tax Law. It spells out key terms that determine the tax base—most importantly an "average market price" construct that the Department of Tax and Fee Administration will compute for arm’s‑length transactions by adding a department-determined mark‑up to wholesale cost, and a separate rule that uses gross receipts for non‑arm’s‑length transactions.
The bill also explicitly includes medicinal cannabis and CBD/synthetic cannabinoids in the statute and defines when product "enters the commercial market" (completion of quality assurance testing).
Why this matters: those definitional choices determine when a taxable event occurs, how much tax is due, and how easily taxpayers and auditors can value transfers. The bill shifts several valuation decisions from market evidence to administrative determination, creating predictability for auditors but new compliance and documentation burdens for industry actors and possible avenues for valuation disputes.
At a Glance
What It Does
The bill defines terms that establish the cannabis tax base and valuation method. For arm’s‑length transfers it requires the Department to set an "average market price" by adding a mark‑up to the wholesale cost; for non‑arm’s‑length transfers it uses the retailer’s gross receipts.
Who It Affects
Retailers, cultivators, distributors, manufacturers, and nonprofits engaged in California cannabis commerce; the California Department of Tax and Fee Administration (CDTFA) for valuation and enforcement; and patients receiving donated medicinal cannabis under Business and Professions Code section 26071.
Why It Matters
By putting valuation authority and certain tax triggers into statute—especially the QA testing requirement for entering the commercial market—the bill alters audit levers, documentation needs, and where disputes over taxable value will concentrate.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2250 does not create a new tax rate; it rewrites and adds definitions that determine how existing cannabis taxes are calculated and enforced. The centerpiece is a two‑track approach to valuation: for arm’s‑length sales the Department will calculate an "average market price" by taking the wholesale cost to the retailer and applying a mark‑up that the Department sets and updates biannually; for non‑arm’s‑length sales the retailer’s gross receipts become the taxable measure. "Arm’s‑length" itself is defined as a voluntary, good‑faith sale at fair market value between informed parties, placing the burden on taxpayers to show a transfer was at arm’s length if they want the mark‑up method to apply.
The bill also ties the moment a product becomes subject to commercial rules to quality assurance testing: cannabis "enters the commercial market" only after it completes testing described in Section 26110 of the Business and Professions Code. That definition makes testing both a public‑health and a tax event, with implications for custody, recordkeeping, and timing of tax liability.
The draft explicitly includes medicinal cannabis, medicinal concentrates, CBD isolate, and synthetic cannabinoids in the statutory definitions, removing ambiguity about whether these product types are within the tax framework.On transfers intended for patient donation, AB 2250 defines "designated for donation" as a cultivator donating to a cannabis retailer for onward donation to a qualified medicinal patient under section 26071. That creates a formal category that can be tracked for compliance and audit purposes.
The bill also references a "2020–21 fiscal year baseline" tied to specific sub‑trust account allocations, linking definitional language to revenue‑allocation mechanics under Section 34019 and the Department of Finance’s determinations.Taken together, the definitions centralize valuation authority with the Department, create a statutory tax trigger tied to QA testing, and formalize donation pathways and product categories that had been handled by cross‑referencing other codes. The result is more administrative clarity about how taxes will be measured—but also more places where taxpayers and auditors are likely to clash over valuation, timing, and recordkeeping.
The Five Things You Need to Know
The bill requires the Department to compute "average market price" for arm’s‑length sales by adding a Department‑set mark‑up to the wholesale cost to the retailer, with that mark‑up updated on a biannual schedule.
For non‑arm’s‑length transactions the statute uses the cannabis retailer’s gross receipts as the taxable measure rather than a Department mark‑up or wholesale cost.
AB 2250 defines "enters the commercial market" as completion of the quality assurance testing regime in Business and Professions Code section 26110, making testing the statutory trigger for commercial status.
The bill creates a formal "designated for donation" category: cultivators may donate to retailers for onward donation to qualified medicinal patients under section 26071, a path that the statute now recognizes for tracking purposes.
The statute ties a "2020–21 fiscal year baseline" to the third allocation of fiscal‑year 2020–21 revenue under Section 34019(f), as determined by the Department of Finance, linking definitions to revenue‑allocation accounting.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: "Cannabis Tax Law"
This provision names the part the "Cannabis Tax Law," clarifying that the definitions and rules that follow are intended to govern the taxation framework. Practically, that labels the subsequent definitions as the statutory lexicon for tax admin, not just loose regulatory guidance—an important signal that these terms will control tax assessments and audits.
2020–21 fiscal year baseline (allocation reference)
The bill defines a specific baseline tied to the third allocation of 2020–21 revenues in the sub‑trust accounts and assigns the Department of Finance the task of determining that amount. That language connects definitional work directly to revenue‑allocation mechanics in Section 34019, which matters for jurisdictions or programs that receive or benchmark against those sub‑trust disbursements.
Arm’s‑length vs non‑arm’s‑length valuation and the Department mark‑up
These clauses set a two‑tier valuation system. Arm’s‑length transfers use an "average market price" calculated from wholesale cost plus a mark‑up the Department sets and updates biannually. Non‑arm’s‑length transfers use retailer gross receipts as the taxable measure. For auditors this creates discrete evidentiary paths: taxpayers must substantiate an arm’s‑length sale to get the mark‑up rule, otherwise gross receipts provide a simpler but often higher base. The biannual mark‑up schedule centralizes price setting in the Department rather than leaving it to sporadic market evidence.
"Designated for donation"—cultivator to retailer to patient pathway
By defining "designated for donation," the bill recognizes a structured donation chain: cultivators may transfer medicinal cannabis to a retailer that will donate it to qualified patients under Business and Professions Code section 26071. That formal recognition matters for tax administration because it creates a labeled category that can be tracked (and audited) separately from commercial sales—though the bill does not itself state the tax treatment or exemptions for those transfers, so documentation will be crucial.
Commercial market trigger, gross receipts, and unprocessed cannabis categories
The statute makes completion of quality assurance testing (per Section 26110) the point at which product "enters the commercial market," which is the relevant status for taxation and other regulatory obligations. It also defines "gross receipts" by reference and lists categories of "unprocessed cannabis," including flowers and leaves, plus shipments to manufacturers. Together these definitions affect custody chains and the timing of tax liability: a failure to complete QA testing delays commercial status and can complicate when tax is due and who must report it.
This bill is one of many.
Codify tracks hundreds of bills on Finance across all five countries.
Explore Finance in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- California Department of Tax and Fee Administration — Gains clear statutory authority to set a mark‑up and a biannual schedule, simplifying audit standards and giving the agency an explicit valuation tool for arm’s‑length transfers.
- Qualified medicinal cannabis patients and donation programs — "Designated for donation" creates a statutorily recognized transfer pathway, which can make donated product easier to document and track for purposes of patient access and program oversight.
- Tax auditors and compliance consultants — The two‑track valuation and the Department’s mark‑up reduce reliance on bespoke market analyses in many cases, enabling more standardized audits and compliance frameworks.
- Local governments and programs tied to sub‑trust allocations — The defined 2020–21 baseline links allocations to a specific accounting determination, which can aid budgeting tied to those sub‑trust receipts.
Who Bears the Cost
- Cannabis retailers — Face increased recordkeeping and valuation work to show whether transfers are arm’s‑length and to apply the Department’s mark‑up or report gross receipts for non‑arm’s‑length sales.
- Cultivators and small operators — Must track donation designations, transfers to retailers, and QA timing; smaller operators may lack systems to capture the required documentation and may face audit risk.
- CDTFA (administration costs) — Must build the rulemaking, biannual mark‑up process, and enforcement operations; those activities create workload and may require new data collection or staffing.
- Laboratories and distributors — Because QA testing is the tax trigger, labs and distributors may face timing pressure and disputes about custody and responsibility if testing delays change tax liabilities.
Key Issues
The Core Tension
The core tension is between predictability and administrative control on one hand—giving the Department a standardized, biannual mark‑up to simplify audits—and market accuracy and operational burden on the other: an administratively set price and a testing‑based tax trigger reduce reliance on messy market evidence but raise compliance costs, create incentives to game timing, and concentrate litigation risk on a few administratively determined inputs.
The bill centralizes valuation power with the Department through a mark‑up mechanism and a biannual update schedule, which creates administrative predictability but shifts substantive price‑setting away from market transactions. That increases the risk of disputes over the mark‑up’s methodology and transparency: taxpayers will want clear rulemaking, data inputs, and appeal paths to challenge an administratively set price.
The statute also distinguishes arm’s‑length from non‑arm’s‑length transfers without prescribing the documentary standard needed to prove an arm’s‑length sale, leaving implementation questions about what records suffice in an audit.
Tying commercial status to quality assurance testing is sensible from a public‑health perspective, but it turns lab capacity and testing timelines into tax levers. Delays or disputes over testing could create timing mismatches between custody and tax liability, incentivize parties to delay testing to postpone taxes, or push transactions into informal channels.
Finally, the bill includes an anomalous temporal clause limiting mark‑up increases between the act’s operative date and July 1, 2021; that creates an unexplained retroactive window or drafting inconsistency that the Department and counsel will need to resolve before enforcement to avoid legal challenges and administrative confusion.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.